{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:05:34Z","timestamp":1784790334885,"version":"3.55.0"},"reference-count":21,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Patients with cystic fibrosis (CF) experience recurrent infections requiring repeated antimicrobial therapy, leading to high rates of multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) and contributing substantially to disease-related mortality. Ceftolozane\/tazobactam (C\/T) is an innovative therapy used to treat resistant Gram-negative infections, with enhanced activity against P. aeruginosa infections. Methods: The Study of Prescribing patterns and Effectiveness of Ceftolozane\/Tazobactam Real-world Analysis (SPECTRA) was a multicenter, retrospective real-world study of hospitalized adults who received \u226548 h of C\/T across seven countries. Medical record data were collected for up to 6 months before treatment and 30 days after the final C\/T dose (or death). This subgroup analysis describes clinical outcomes and healthcare resource utilization (HCRU) among hospitalized adults with CF who received C\/T for an index infection. Results: Of 64 patients with CF, 53.1% had MDR P. aeruginosa. Clinical success was achieved in 78.1% of patients, with highest and lowest success rates in patients treated with C\/T as second (100%) and sixth or later (40.0%) treatment. Microbial eradication was reported in 10.9% of patients. In-hospital mortality occurred in 14.1% of patients, with the lowest percentage in patients treated with C\/T as first or second line treatment (0.0%) and the highest in patients treated with C\/T sixth or later (40.0%). Median LOS was 31.5 days. Readmission (30-day all-cause) occurred in 10.9% of patients. Conclusions: In this SPECTRA subgroup analysis, C\/T was associated with favorable real-world clinical outcomes among hospitalized adults with CF treated for an index infection. Interpretation is limited by the retrospective design, heterogeneous infection indications\/sites, and limited interpretability of microbiologic endpoints in CF.<\/jats:p>","DOI":"10.3390\/antibiotics15080715","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:11:42Z","timestamp":1784787102000},"page":"715","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes and Healthcare Resource Utilization Results Among Hospitalized Adults with Cystic Fibrosis Treated with Ceftolozane\/Tazobactam: A SPECTRA Real-World Subgroup Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-9526","authenticated-orcid":false,"given":"Emre","family":"Yucel","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., 351 North Sumneytown Pike, P.O. Box 1000, North Wales, PA 19454, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic, Carrer de Villarroel, 170, L\u2019Eixample, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-8229","authenticated-orcid":false,"given":"Florian","family":"Thalhammer","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Allen","sequence":"additional","affiliation":[{"name":"MSD (UK) Limited, 120 Moorgate, London EC2M 6UR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Levy","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 351 North Sumneytown Pike, P.O. Box 1000, North Wales, PA 19454, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huina","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tan Tock Seng Hospital, 11 Jln Tan Tock Seng, Singapore 308433, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Kaul","sequence":"additional","affiliation":[{"name":"Royal Brompton & Harefield NHS Foundation Trust, Britten St, London SW3 6PY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Perikleous, E.P., Gkentzi, D., Bertzouanis, A., Paraskakis, E., Sovtic, A., and Fouzas, S. (2023). Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020217"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: Basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Anim. Models Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2022.08.010","article-title":"Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection\u2014A European cystic fibrosis patient registry data analysis","volume":"22","author":"Orenti","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"ofae391","DOI":"10.1093\/ofid\/ofae391","article-title":"Ceftolozane\/Tazobactam for the Treatment of Adults with Cystic Fibrosis: Results from a French Prospective Cohort Study","volume":"11","author":"Burgel","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2217\/fmb.15.117","article-title":"Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin","volume":"10","author":"Ehsan","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Losito, A.R., Raffaelli, F., Del Giacomo, P., and Tumbarello, M. (2022). New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11050579"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Curtis","year":"2015","journal-title":"Trials"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/cpt.3713","article-title":"FRAME: Framework for Real-World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy\/Effectiveness\u2014An Evaluation of Regulatory and Health Technology Assessment Decision Making","volume":"118","author":"Candore","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jgar.2025.06.015","article-title":"Real-world analysis of ceftolozane\/tazobactam prescribing patterns and effectiveness: SPECTRA analysis on chronic pulmonary diseases and respiratory-related infections","volume":"44","author":"Yucel","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"116737","DOI":"10.1016\/j.diagmicrobio.2025.116737","article-title":"A real-world investigation into prescribing patterns and effectiveness of ceftolozane\/tazobactam among critically ill patients from SPECTRA","volume":"111","author":"Soriano","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jgar.2025.01.007","article-title":"Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane\/Tazobactam Real-world Analysis (SPECTRA)","volume":"41","author":"Soriano","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/mdr.2016.0048","article-title":"Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates","volume":"23","author":"Rutter","year":"2017","journal-title":"Microb. Drug Resist."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Vitiello, A., Blasi, F., Sabbatucci, M., Zovi, A., Miele, F., Ponzo, A., Langella, R., and Boccellino, M. (2024). The Impact of Antimicrobial Resistance in Cystic Fibrosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061711"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100246","DOI":"10.1016\/j.bioflm.2024.100246","article-title":"Cystic fibrosis and the clinical biofilm revolution A survey of the Danish CF Center\u2019s contribution","volume":"9","year":"2025","journal-title":"Biofilm"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e000020","DOI":"10.1136\/bmjoq-2017-000020","article-title":"Improving the care of patients with cystic fibrosis (CF)","volume":"6","author":"Khan","year":"2017","journal-title":"BMJ Open Qual."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary Exacerbations in Adults with Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"key":"ref_18","unstructured":"International Society for Pharmacoepidemiology (ISPE) (2026, January 26). Guidelines for Good Pharmacoepidemiology Practices (GPP) [Updated June 2015]. Available online: https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/."},{"key":"ref_19","unstructured":"World Medical Association (2026, January 26). Declaration of Helsinki [Updated October 2024]. Available online: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/."},{"key":"ref_20","unstructured":"European Medicines Agency (2026, January 26). Guideline on Good Pharmacovigilance Practices (GVP): Module VI\u2014Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev 2) [Updated 22 November 2017]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf."},{"key":"ref_21","unstructured":"European Parliament and Council (2026, January 26). EU General Data Protection Regulation\u2014Regulation (EU) 2016\/679 [Updated 27 April 2016]. Available online: http:\/\/data.europa.eu\/eli\/reg\/2016\/679\/2016-05-04."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/715\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:24:01Z","timestamp":1784787841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["antibiotics15080715"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15080715","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}